Integrated DNA Technologies (IDT) unveiled its latest stride in the realm of synthetic biology, announcing the inauguration of a sprawling 25,000 square-foot facility in Coralville, Iowa. This expansion marks a significant augmentation of its synthetic biology operations, doubling its footprint in this critical field.

“The expansion of our synthetic biology manufacturing operations adds significant capacity for IDT and lays the foundation for the future growth of our synthetic biology product portfolio,” says Demaris Mills, President, IDT. “With this increased footprint, we will be introducing new product enhancements, which will include the launch of a rapid gene synthesis offering expected in late Q2. This investment provides IDT with a growth runway for its synthetic biology product portfolio and manufacturing arm to support the rapidly expanding global DNA synthesis market and related drug development activity.”

Central to IDT's expansion strategy is the introduction of novel product enhancements, slated to include the launch of a rapid gene synthesis offering by late Q2. This strategic investment not only amplifies IDT's synthetic biology arsenal but also positions the company as a frontrunner in catering to the burgeoning global DNA synthesis market and the concomitant surge in drug development endeavors.

Strategically situated in close proximity to IDT's flagship U.S. headquarters, the state-of-the-art facility boasts an array of cutting-edge amenities tailored to foster innovation. Over half of the facility's expanse is dedicated to sophisticated synthetic biology lab spaces, complemented by well-appointed office quarters and conference rooms. Notable features include enhanced cold storage facilities, streamlined flow designed for lean manufacturing, and eco-friendly LED lighting systems, underscoring IDT's commitment to sustainability.

The inauguration follows hot on the heels of IDT's recent launch of a custom vector onboarding tool, aimed at streamlining researchers' workflows and expediting functional studies with meticulously verified clonal DNA. This addition bolsters IDT's expansive synthetic biology portfolio, which encompasses a diverse array of gene and gene fragment offerings, catering to a wide spectrum of research needs.

Notably, this landmark expansion is not IDT's first foray into facility augmentation. In late 2023, the company unveiled its state-of-the-art Therapeutic Oligonucleotide Manufacturing facility, signaling its foray into the realm of therapeutics—a move indicative of IDT's relentless pursuit of innovation and its unwavering commitment to pushing the boundaries of scientific exploration.